Search Result

Results for "

Histone Acetyltransferase

" in MCE Product Catalog:

By Targets:	Histone Acetyltransferase (37) Histone Demethylase (1) Aldehyde Dehydrogenase (ALDH) (1) Apoptosis (9) Autophagy (2) Bacterial (1) Cholinesterase (ChE) (2) Endogenous Metabolite (1) Epigenetic Reader Domain (6) Ferroptosis (1) Influenza Virus (1) Keap1-Nrf2 (1) Mitophagy (1) STAT (1)
By Research Areas:	Cancer (37) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (5)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Targets Recommended: Histone Acetyltransferase Histone Methyltransferase Histone Demethylase HDAC

Cat. No.	Product Name	Target	Research Areas

HY-100734

Histone Acetyltransferase Inhibitor II	Histone Acetyltransferase	Cancer
Histone Acetyltransferase Inhibitor II (compound 2c) is a potent, selective and cell permeable p300 histone acetyltransferase inhibitor, with an IC₅₀ of 5 µM. Histone Acetyltransferase Inhibitor II shows anti-acetylase activity in mammalian cells.

HY-129039

Butyrolactone 3 MB-3	Histone Acetyltransferase	Cancer Metabolic Disease Inflammation/Immunology Neurological Disease
Butyrolactone 3 (MB-3) is a specifical small-molecule inhibitor of the histone acetyltransferase Gcn5 (IC₅₀=100 μM), which has a high affinity to the Gcn5 enzyme comparable to that of its natural substrate, histone H3. Butyrolactone 3 shows weak inhibitory on CBP (IC₅₀=0.5 mM). Butyrolactone 3 can be used in studies of cancer, metabolic, autoimmune and neurological diseases.

HY-W013274A

CPTH2 hydrochloride	Histone Acetyltransferase Apoptosis	Cancer
CPTH2 hydrochloride is a potent histone acetyltransferase (HAT) inhibitor. CPTH2 hydrochloride selectively inhibits the acetylation of histone H3 by Gcn5. CPTH2 hydrochloride induces apoptosis and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of acetyltransferase p300 (KAT3B).

HY-W013274

CPTH2	Histone Acetyltransferase Apoptosis	Cancer
CPTH2 is a potent histone acetyltransferase (HAT) inhibitor. CPTH2 selectively inhibits the acetylation of histone H3 by Gcn5. CPTH2 induces apoptosis and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of acetyltransferase p300 (KAT3B).

HY-147261

B026	Histone Acetyltransferase	Cancer
B026 is a selective, potent, orally active *p300/CBP histone* acetyltransferase (HAT) inhibitor with IC₅₀** values of 1.8 nM and 9.5 nM for p300 and CBP enzyme, respectively. B026 has anticancer activity for androgen receptor-positive (AR+) prostate cancer cell lines.

HY-131035

Lys-CoA TFA	Histone Acetyltransferase	Cancer
Lys-CoA TFA is a selective p300 histone acetyltransferase (HAT) inhibitor (IC₅₀=50-500 nM). Lys-CoA TFA displays >100-fold selectivity for p300 over PCAF (IC₅₀=200 μM). Lys-CoA TFA inhibits p300 HAT activity-dependent transcriptional activation.

HY-116673

TTK21	Histone Acetyltransferase	Neurological Disease
TTK21 is an activator of the histone acetyltransferases CBP/p300. TTK21 passes the blood–brain barrier, induces no toxicity, and reaches different parts of the brain when conjugated to glucose-based carbon nanosphere (CSP). TTK21 has beneficial implications for the brain functions of adult neurogenesis and long-term memory.

HY-13823

C646	Histone Acetyltransferase Autophagy Epigenetic Reader Domain Apoptosis	Cancer
C646 is a selective and competitive histone acetyltransferase p300 inhibitor with K_i of 400 nM, and is less potent for other acetyltransferases.

HY-123604A

TH1834 dihydrochloride	Histone Acetyltransferase Apoptosis	Cancer
TH1834 dihydrochloride is a specific Tip60 (KAT5) histone acetyltransferase inhibitor. TH1834 dihydrochloride induces apoptosis and increases DNA damage in breast cancer. TH1834 dihydrochloride does not affect the activity of related histone acetyltransferase MOF. Anticancer activity.

HY-102060

WM-8014
Histone Acetyltransferase Cancer

WM-8014 is an inhibitor of MOZ, a member of histone acetyltransferases, with an IC₅₀ of 55 nM.

WM-8014	Histone Acetyltransferase	Cancer
WM-8014 is an inhibitor of MOZ, a member of **histone acetyltransferases, with an IC₅₀** of 55 nM.

HY-123604

TH1834	Histone Acetyltransferase Apoptosis	Cancer
TH1834 is a specific *Tip60 (KAT5) histone* acetyltransferase (HAT) inhibitor. TH1834 induces apoptosis** and increases DNA damage in breast cancer. TH1834 does not affect the activity of related histone acetyltransferase MOF. Anticancer activity.

HY-102059

MOZ-IN-2
Histone Acetyltransferase Cancer

MOZ-IN-2 is an inhibitor of protein MOZ, a member of histone acetyltransferases, with an IC₅₀ of 125 μM.

MOZ-IN-2	Histone Acetyltransferase	Cancer
MOZ-IN-2 is an inhibitor of protein MOZ, a member of histone acetyltransferases, with an IC₅₀ of 125 μM.

HY-143442

CBP/p300-IN-18	Histone Acetyltransferase	Cancer
CBP/p300-IN-18 (compound 8) is a potent EP300/CBP HAT inhibitor with IC₅₀s of 0.056, 0.46 µM for HAT EP300 and LK2 H3K27, respectively.

HY-143440

CBP/p300-IN-16
Histone Acetyltransferase Cancer

CBP/p300-IN-16 (compound 1) is a potent EP300/CBP HAT inhibitor with IC₅₀s of 0.61, 2.24 µM for HAT EP300 and LK2 H3K27, respectively.
HY-143441

CBP/p300-IN-17
Histone Acetyltransferase Cancer

CBP/p300-IN-17 (compound 7) is a potent EP300/CBP HAT inhibitor with IC₅₀s of 0.18, 0.69 µM for HAT EP300 and LK2 H3K27, respectively.
HY-138945

SYY-B085-1
Histone Acetyltransferase Cancer

SYY-B085-1 is a histone acetyltransferase (HAT) inhibitor extracted from patent WO2019201291A1.
HY-134964

CTB
Histone Acetyltransferase Apoptosis Cancer Neurological Disease

CTB is a potent p300 histone acetyltransferase activator. CTB can effectively induce apoptosis in MCF-7 cells.

CBP/p300-IN-16	Histone Acetyltransferase	Cancer
CBP/p300-IN-16 (compound 1) is a potent EP300/CBP HAT inhibitor with IC₅₀s of 0.61, 2.24 µM for HAT EP300 and LK2 H3K27, respectively.

CBP/p300-IN-17	Histone Acetyltransferase	Cancer
CBP/p300-IN-17 (compound 7) is a potent EP300/CBP HAT inhibitor with IC₅₀s of 0.18, 0.69 µM for HAT EP300 and LK2 H3K27, respectively.

SYY-B085-1	Histone Acetyltransferase	Cancer
SYY-B085-1 is a histone acetyltransferase (HAT) inhibitor extracted from patent WO2019201291A1.

CTB	Histone Acetyltransferase Apoptosis	Cancer Neurological Disease
CTB is a potent p300 histone acetyltransferase activator. CTB can effectively induce apoptosis in MCF-7 cells.

HY-N0005

Curcumin Diferuloylmethane; Natural Yellow 3; Turmeric yellow	Histone Acetyltransferase Epigenetic Reader Domain Keap1-Nrf2 Autophagy Mitophagy Influenza Virus Ferroptosis	Cancer
Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.

HY-W015239

KAT8-IN-1	Others	Cancer Inflammation/Immunology
KAT8-IN-1 is a *lysine (K) acetyltransferase* 8 (KAT8) inhibitor, with IC₅₀s of 141 μM (KAT8), 221 μM (KAT2B), 106 μM (KAT3B), respectively. KAT8** inhibits histone acetyltransferases (HATs), and could result in disease states, such as cancer or inflammatory diseases.

HY-N2020

Anacardic Acid Hydroginkgolic acid; Ginkgolic Acid C15:0	Histone Acetyltransferase Epigenetic Reader Domain Bacterial	Cancer
Anacardic Acid, extracted from cashew nut shell liquid, is a **histone acetyltransferase inhibitor, inhibits HAT activity of p300 and PCAF, with IC₅₀**s of ∼8.5 μM and ∼5 μM, respectively.

HY-128876

CBP/p300-IN-3
Histone Acetyltransferase Cancer

CBP/p300-IN-3, a p300/CBP histone acetyltransferase inhibitor, Compound 6, is sourced from patent WO 2019049061 A1.

CBP/p300-IN-3	Histone Acetyltransferase	Cancer
CBP/p300-IN-3, a p300/CBP **histone acetyltransferase** inhibitor, Compound 6, is sourced from patent WO 2019049061 A1.

HY-114566

SPV106	Histone Acetyltransferase	Metabolic Disease
SPV106 is histone acetylase (HAT) and GCN5-related N-acetyltransferases (GNAT) activator. SPV106 can be used for the research of type 2 diabetes (T2D).

HY-107455

A-485	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
A-485 is a potent and selective catalytic inhibitor of p300/CBP with IC₅₀s of 9.8 nM and 2.6 nM for p300 and CBP histone acetyltransferase (HAT), respectively.

HY-128875

CBP/p300-IN-10	Histone Acetyltransferase	Cancer
CBP/p300-IN-10 is a highly potent histone acetyltransferase EP300 and CREBBP with IC₅₀ values of 26 nM and 39 nM, respectively. CBP/p300-IN-10 can be used to research anticancer.

HY-136285

CPI-1612	Histone Acetyltransferase	Cancer
CPI-1612 is a highly potent, orally active *EP300/CBP histone* acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT**. CPI-1612 has an anticancer activity.

HY-100132

CBP/p300-IN-5	Histone Acetyltransferase	Cancer
P300/CBP-IN-5 is a potent p300/CBP histone acetyltransferase inhibitor extracted from patent WO2016044770A1, Example 715, has an IC₅₀ of 18.8 nM.

HY-139149

NiCur	Histone Acetyltransferase	Cancer
NiCur is a potent and selective *CBP histone* acetyltransferase (HAT) inhibitor with an IC₅₀ value of 0.35 μΜ. NiCur, which blocks CBP HAT** activity and downregulates p53 activation upon genotoxic stress. NiCur can be used for performing mechanistic studies without affecting the expression of target proteins.

HY-147290

NSC 694623	Histone Acetyltransferase	Cancer
NSC 694623 is a potent histone acetyltransferase (HAT) inhibitor with an IC₅₀ value of 15.9 μM for recombinant HAT p300/CBP-associated factor (PCAF). NSC 694623 has antiproliferative activity against certain cancer cells. NSC 694623 can be used for researching anticancer.

HY-16531A

YF-2 hydrochloride	Histone Acetyltransferase	Cancer Neurological Disease
YF-2 hydrochloride is a highly selective, blood-brain-barrier permeable **histone acetyltransferase activator, acetylates H3 in the hippocampus, with EC₅₀**s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer's disease.

HY-16706A

Remodelin hydrobromide	Histone Acetyltransferase	Cancer
Remodelin, a specific inhibitor of N-acetyltransferase NAT10, can ameliorate Hutchinson-Gilford Progeria Syndrom (HGPS) cellular phenotypes. Remodelin acts in a progerin- and FTI-independent pathway, by targeting and inhibiting NAT10. NAT10 is a protein with histone acetylation activity and primarily identified to be involved in regulation of telomerase activity.

HY-16531

YF-2	Histone Acetyltransferase	Cancer Neurological Disease
YF-2 is a highly selective, blood-brain-barrier permeable **histone acetyltransferase activator, acetylates H3 in the hippocampus, with EC₅₀**s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer's disease.

HY-110127

NU9056	Histone Acetyltransferase Apoptosis	Cancer
NU9056 is a potent and selective Tip60 (KAT5) histone acetyltransferase inhibitor with an of 2 µM. NU9056 shows >16-fold selectivity for Tip60 over PCAF, p300 and GCN5. NU9056 induces apoptosis of prostate cancer cells.

HY-143339

CBP/p300-IN-15	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-15 (compound 13a) is a potent p300/CBP inhibitor, with IC₅₀ values of 2.50 and 28.0 nM, respectively. CBP/p300-IN-15 shows good activity against OVCAR-3 and A2780 cell line, with EC₅₀ values of 0.865 and 2.71 μM, respectively. CBP/p300-IN-15 can be used for ovarian cancer research.

HY-143443

DS17701585	Histone Acetyltransferase Histone Demethylase	Cancer
DS17701585 (Compound 11) is a highly selective, orally active EP300 and CBP inhibitor with IC₅₀ values of 0.040, 0.15, 0.45 and 0.70 µM against CBP, EP300, H3K27 and SOX2. DS17701585 can be used for cancer research.

HY-124696

PU139	Histone Acetyltransferase	Cancer
PU139 is a potent pan-histone acetyltransferase (HAT) inhibitor. PU139 blocks the HATs Gcn5, p300/CBP-associated factor (PCAF), CREB (cAMP response element-binding) protein (CBP) and p300 with IC₅₀s of 8.39, 9.74, 2.49 and 5.35 μM, respectively.

HY-132197

CBP/p300-IN-12	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-12 is a potent and selective covalent histone acetyltransferases p300 (IC₅₀ of 166 nM) and CBP inhibitor. CBP/p300-IN-12 decreases the levels of H3K27Ac of PC-3 cells (EC₅₀ of 37 nM). CBP/p300-IN-12 forms a covalent adduct with C1450.

HY-100671

L002	Histone Acetyltransferase STAT	Cancer Inflammation/Immunology
L002 is a potent, cell permeable, reversible and specific acetyltransferase p300 (KAT3B) inhibitor with an IC₅₀ of 1.98 μM. L002 binds the acetyl-CoA pocket and competitively inhibits the FATp300 catalytic domain, blocks histone acetylation and p53 acetylation, and inhibits STAT3 activation. L002 has the potential for hypertension‐induced cardiac hypertrophy and fibrogenesis treatment.

HY-107569

Garcinol	Cholinesterase (ChE) Histone Acetyltransferase Apoptosis Endogenous Metabolite	Cancer Inflammation/Immunology
Garcinol, a polyisoprenylated benzophenone harvested from Garcinia indica, exerts anti-cholinesterase properties towards acetyl cholinesterase (AChE) and butyrylcholinesterase (BChE) with IC₅₀s of 0.66 µM and 7.39 µM, respectively. Garcinol also inhibits **histone acetyltransferases (HATs, IC₅₀= 7 μM) and p300/CPB-associated factor (PCAF, IC₅₀** = 5 μM). Garcinol has anti-inflammatory and anti-cancer activity.

HY-138097

α-NETA	Aldehyde Dehydrogenase (ALDH) Cholinesterase (ChE) Apoptosis	Cancer
α-NETA is a potent and noncompetitive choline acetyltransferase (ChA) inhibitor with an IC₅₀ of 9 μM. α-NETA is a potent ALDH1A1 (IC₅₀=0.04 µM) and chemokine-like receptor-1 (CMKLR1) antagonist. α-NETA weakly inhibits cholinesterase (ChE; IC₅₀=84 µM) and acetylcholinesterase (AChE; IC₅₀=300 µM). α-NETA has anti-cancer activity.

Cat. No.	Product Name

HY-L024

Histone Modification Research Compound Library	521 compounds
A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases. MCE owns a unique collection of 521 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

Histone Modification Research Compound Library

521 compounds

A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.

MCE owns a unique collection of 521 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

HY-L005

Epigenetics Compound Library	1037 compounds
Epigenetics refers to changes in phenotype that are not rooted in DNA sequence. Many types of epigenetic processes have been identified, including DNA methylation, alteration in the structure of histone proteins and gene regulation by small noncoding microRNAs. Modification of DNA, protein, or RNA, resulting in changes to the function and/or regulation of these molecules, without altering their primary sequences, reveals the complexities of cellular differentiation, embryology, the regulation of gene expression, aging, cancer, and other diseases. MCE provide a unique collection of 1037 epigenetics-related compounds that can be used in the research of the related diseases.

Epigenetics Compound Library

1037 compounds

Epigenetics refers to changes in phenotype that are not rooted in DNA sequence. Many types of epigenetic processes have been identified, including DNA methylation, alteration in the structure of histone proteins and gene regulation by small noncoding microRNAs. Modification of DNA, protein, or RNA, resulting in changes to the function and/or regulation of these molecules, without altering their primary sequences, reveals the complexities of cellular differentiation, embryology, the regulation of gene expression, aging, cancer, and other diseases.

MCE provide a unique collection of 1037 epigenetics-related compounds that can be used in the research of the related diseases.

Cat. No.	Product Name	Target	Research Area

HY-P2557

Histone H3 (5-23)
Peptides Others

Histone H3 (5-23), derived from histone H3 5-23 amino acids, can be used as a substrate for histone acetyltransferase (HAT) assays.

Histone H3 (5-23)	Peptides	Others
Histone H3 (5-23), derived from histone H3 5-23 amino acids, can be used as a substrate for histone acetyltransferase (HAT) assays.

HY-P2552

Histone H3 (1-21)	Peptides	Others
Histone H3 (1-21), derived from Histone H3 1-21 amino acids, is usually used as a substrate for methyltransferase (Histone 3 K4 and K9) and acetyltransferase (Histone 3 K9 and K14) assays.

Cat. No.	Product Name	Target	Category